Unusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC

被引：0
|
作者：
Sonkusare, Shipra [1 ,2 ]
Prasannakumar, Somashekhar Sampige [3 ]
Ahuja, Vijay [1 ]
Kumar, Rohit [3 ]
机构：
[1] Aster Hosp Inc, Gynaecol Oncol, Bangalore, Karnataka, India
[2] All India Inst Med Sci Nagpur, Obstet & Gynaecol, Nagpur, Maharashtra, India
[3] Aster Hosp Inc, Surg Oncol, Bangalore, Karnataka, India
来源：
BMJ CASE REPORTS | 2025年 / 18卷 / 01期
关键词：
Cancer - see Oncology; Obstetrics and gynaecology; Cancer; Oncology; CHEMOTHERAPY; BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; SURVIVAL; TRIAL;
D O I：
10.1136/bcr-2024-262137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ovarian cancer is the second most fatal gynaecological malignancy. The relapses after treatment of ovarian cancer usually occur within 2 years after completion of the first-line therapy. Recurrent ovarian cancer commonly presents as peritoneal surface deposits in the abdomen with or without ascites. A delayed relapse presenting as a solitary lesion in the urinary bladder wall is unusual in patients treated for advanced ovarian cancer. We report the successful management of a case of solitary metastasis of ovarian cancer in the urinary bladder wall, which occurred more than 6 years after achieving a complete remission state.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery
    Perrin, Morgane
    Bentivegna, Enrica
    Bonneau, Claire
    Uzan, Catherine
    Leary, Alexandra
    Pautier, Patricia
    Genestie, Catherine
    Morice, Philippe
    Gouy, Sebastien
    ANTICANCER RESEARCH, 2018, 38 (04) : 2247 - 2252
  • [22] Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Chambers, Laura M.
    Yao, Meng
    Morton, Molly
    Gruner, Morgan
    Chichura, Anna
    Horowitz, Max
    Costales, Anthony B.
    Rose, Peter G.
    Michener, Chad M.
    Debernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2021, 161 (02) : 389 - 395
  • [23] The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer
    Ortega, Silvia
    Angel Minguez, Jose
    Manuel Aramendia, Jose
    Santisteban, Marta
    Martinez-Regueira, Fernando
    Marti-Cruchaga, Pablo
    Luis Alcazar, Juan
    Jurado, Matias
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2020, 41 (04) : 523 - 530
  • [24] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [25] Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy
    Lee, Jung-Yun
    Lee, Yong Jae
    Son, Joo-Hyuk
    Kim, Sunghoon
    Choi, Min Chul
    Suh, Dong Hoon
    Song, Jae-Yun
    Hong, Dae Gy
    Kim, Mi Kyung
    Kim, Jae-Hoon
    Chang, Suk-Joon
    JAMA SURGERY, 2023, 158 (11) : 1133 - 1140
  • [26] Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
    Son, Joo-Hyuk
    Dong, Su Ryeon
    Kim, Jisoo
    Kim, Jeeyeon
    Kong, Tae-Wook
    Chang, Suk-Joon
    BMC SURGERY, 2023, 23 (01)
  • [27] Hyper:thermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis
    Huo, Y. R.
    Richards, A.
    Liauw, W.
    Morris, D. L.
    EJSO, 2015, 41 (12): : 1578 - 1589
  • [28] Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer
    Koole, S. N.
    Kieffer, J. M.
    Sikorska, K.
    van Leeuwen, J. H. Schagen
    Schreuder, H. W. R.
    Hermans, R. H.
    de Hingh, I. H.
    van der Velden, J.
    Arts, H. J.
    van Ham, M. A. P. C.
    Aalbers, A. G.
    Verwaal, V. J.
    Van de Vijver, K. K.
    Sonke, G. S.
    van Driel, W. J.
    Aaronson, N. K.
    EJSO, 2021, 47 (01): : 101 - 107
  • [29] Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer
    Du, Xinjie
    Lin, Xiaojie
    JOURNAL OF BUON, 2019, 24 (05): : 2035 - 2040
  • [30] Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis
    Chua, Terence C.
    Liauw, Winston
    Robertson, Greg
    Morris, David L.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (01) : 166 - 168
12345